Overview

Study of Endostar Subcutaneous Injection in NSCLC

Status:
Unknown status

Trial end date:
2016-09-01

Target enrollment:

Participant gender:

Summary

This is an open-label, single-arm study to assess the safety, tolerability and pharmacokinetics of Endostar subcutaneous injection in Chinese advanced NSCLC patients.

Phase:

Phase 1

Details

Lead Sponsor:

Jiangsu Simcere Pharmaceutical Co., Ltd.

Treatments:

Endostar protein